Eli Lil­ly is mak­ing a $1.8B leap in­to the mR­NA field, tar­get­ing next-gen can­cer vac­cines

Eli Lil­ly is div­ing in­to the mes­sen­ger RNA are­na, sign­ing off on a heav­i­ly back-end­ed $1.8 bil­lion deal with Ger­many’s Cure­Vac to de­vel­op up to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA